March 27, 2020 / Clinical Trials

Pfizer Shares Update on PF-06939926 Gene Therapy Trial and COVID-19

Pfizer has shared an update regarding the PF-06939926 gene therapy trial and COVID-19.

Read Pfizer’s update:

Our Clinical Trials

UPDATE: March 25 —To avoid adding to the demands on the healthcare system during this unprecedented crisis with COVID-19, we are pausing for three weeks the recruitment portion of our new and ongoing global interventional clinical studies. We are taking this action in the interests of public health, so that our clinical site partners and we can concentrate on caring for patients in our ongoing clinical trials.

The pause will not affect China, Japan and South Korea, where recruitment will continue. This pause will also not apply to trials that are recruiting individuals with life-threatening conditions who have few or no other therapeutic options, including several oncology studies and our DMD gene therapy program. In addition, this decision will not affect studies that are already fully recruited.

Patients in our ongoing trials will not be impacted by this decision.
We have an important responsibility to the patients currently in our clinical trials. This decision will allow our investigators and us to focus on those individuals.

We will review this decision in three weeks and provide another update then. We expect over time to resume recruitment and new study starts on a country-by-country basis.

Importantly, this decision will not affect the start of our COVID-19 vaccine study with BioNTech, nor our intent to move with unprecedented speed in developing our antiviral and other compounds that may be useful in this crisis.

Read the update

Join Our Mailing List